Advertisement
BIIB or BMRN or NBIX
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileBMRN’s FA Score has 0 green FA rating(s), and NBIX’s FA Score reflects 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- BMRN’s FA Score: 0 green, 5 red.
- NBIX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 2 TA indicator(s) are bullish while BMRN’s TA Score has 4 bullish TA indicator(s), and NBIX’s TA Score reflects 5 bullish TA indicator(s).
- BIIB’s TA Score: 2 bullish, 6 bearish.
- BMRN’s TA Score: 4 bullish, 6 bearish.
- NBIX’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -3.18% price change this week, while BMRN (@Biotechnology) price change was -5.80% , and NBIX (@Pharmaceuticals: Generic) price fluctuated -3.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.93%. For the same industry, the average monthly price growth was +4.86%, and the average quarterly price growth was +10.69%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.53%. For the same industry, the average monthly price growth was +20.28%, and the average quarterly price growth was +17.63%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.07%. For the same industry, the average monthly price growth was +12.01%, and the average quarterly price growth was +83.61%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 22, 2025.
BMRN is expected to report earnings on Oct 22, 2025.
NBIX is expected to report earnings on Nov 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-0.93% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.53% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+5.07% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| BIIB | BMRN | NBIX | |
| Capitalization | 18.8B | 11B | 12.3B |
| EBITDA | 2.79B | 777M | 557M |
| Gain YTD | -16.296 | -13.571 | -9.187 |
| P/E Ratio | 12.50 | 16.76 | 36.99 |
| Revenue | 10B | 2.95B | 2.51B |
| Total Cash | 2.76B | 1.27B | 976M |
| Total Debt | 6.6B | 602M | 439M |
BIIB | BMRN | NBIX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 15 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 58 Fair valued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 73 | 70 | 58 | |
PRICE GROWTH RATING 1..100 | 62 | 78 | 59 | |
P/E GROWTH RATING 1..100 | 94 | 99 | 74 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMRN's Valuation (58) in the Biotechnology industry is in the same range as NBIX (75) and is in the same range as BIIB (90). This means that BMRN's stock grew similarly to NBIX’s and similarly to BIIB’s over the last 12 months.
BMRN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NBIX (100) and is in the same range as BIIB (100). This means that BMRN's stock grew similarly to NBIX’s and similarly to BIIB’s over the last 12 months.
NBIX's SMR Rating (58) in the Biotechnology industry is in the same range as BMRN (70) and is in the same range as BIIB (73). This means that NBIX's stock grew similarly to BMRN’s and similarly to BIIB’s over the last 12 months.
NBIX's Price Growth Rating (59) in the Biotechnology industry is in the same range as BIIB (62) and is in the same range as BMRN (78). This means that NBIX's stock grew similarly to BIIB’s and similarly to BMRN’s over the last 12 months.
NBIX's P/E Growth Rating (74) in the Biotechnology industry is in the same range as BIIB (94) and is in the same range as BMRN (99). This means that NBIX's stock grew similarly to BIIB’s and similarly to BMRN’s over the last 12 months.
| BIIB | BMRN | NBIX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 77% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 62% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 69% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 65% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 64% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 61% | 2 days ago 58% |
| Advances ODDS (%) | 8 days ago 53% | 8 days ago 59% | 14 days ago 72% |
| Declines ODDS (%) | 14 days ago 70% | 2 days ago 62% | 2 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 65% | 2 days ago 70% |
| Aroon ODDS (%) | N/A | 2 days ago 53% | 2 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MGOV | 20.21 | 0.02 | +0.10% |
| First Trust Intermediate Gvt Opps ETF | |||
| QQQD | 14.65 | 0.01 | +0.07% |
| Direxion Daily Concentrated Qs Bear 1X Shares | |||
| BILZ | 100.97 | N/A | N/A |
| PIMCO Ultra Short Government Active ETF | |||
| XCEM | 34.61 | -0.02 | -0.06% |
| Columbia EM Core ex-China ETF | |||
| QQQG | 23.06 | -0.15 | -0.65% |
| Pacer Nasdaq 100 Top 50 Csh CwsGrLdrsETF | |||
NBIX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with LFCR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then LFCR could also see price increases.
| Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
|---|---|---|---|---|
| NBIX | 100% | -0.84% | ||
| LFCR - NBIX | 36% Loosely correlated | -0.28% | ||
| CGC - NBIX | 32% Poorly correlated | +26.11% | ||
| TLRY - NBIX | 29% Poorly correlated | +41.82% | ||
| ELAN - NBIX | 29% Poorly correlated | +2.58% | ||
| AQST - NBIX | 28% Poorly correlated | -1.28% | ||
More | ||||